Side effects are occasionally seen, as with all other drugs in this group. The main ones are gastro-intestinal upset. If vomiting or diarrhoea is seen then treatment should be stopped and veterinary advice sought. Carprogesic is very safe and effective for the vast majority of dogs as long as it is not given to dehydrated or physically ill individuals. Care must be taken if it is used in dogs with pre-existing liver or kidney conditions, as this can lead to adverse reactions.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Pfizer Limited
Address: Ramsgate Road
Sandwich
Kent CT13 9NJ
Telephone: 0845 300 8034 (Out of hours: 01304 616161)
Fax: 01737 332521
Email: UKVetLine@pfizer.com
Website: www.pfizerah.co.uk
Presentation
A white/off white circular tablet for oral administration. Carprogesic Tablets are available in two strengths with the following active composition:
20 mg Carprofen
50 mg Carprofen
Uses
In the dog, Carprogesic Tablets are indicated for the reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain.
Dosage and administration
For oral administration to dogs.
4 mg carprofen per kg bodyweight per day.
An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses. The daily dose may be reduced, subject to clinical response.
Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision.
Do not exceed the stated dose. To extend analgesic and anti-inflammatory cover post-operatively parenteral pre-operative treatment with an injectable carprofen product may be followed with carprofen tablets at 4 mg/kg/day for 5 days.
Contra-indications, warnings, etc
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in puppies less than 4 months of age.
Do not use in case of hypersensitivity to active substance or to any of the excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.
Use in aged dogs may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
In the absence of any specific studies in pregnant target bitches, such use is not indicated.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
Do not administer NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrheoa, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought. As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.
Operator warnings
In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet. Wash hands after handling the product.
Pharmaceutical precautions
Do not store above 25°C. Store in a dry place.
Dispose of used packaging in the household refuse. Unused product should be returned to the veterinary surgeon.
Keep out of reach and sight of children.
For animal treatment only.
Legal category
POM-V
Packaging Quantities
100 x 20 mg tablets per tub or carton (containing 10 blister strips).
100 x 50 mg tablets per tub or carton (containing 10 blister strips).
500 x 50 mg tablets per tub or carton (containing 5 x 10 blister strips).
Not all pack sizes may be marketed.
Further information
Nil.
Marketing Authorisation Holder (if different to distributor)
Norbrook Laboratories Limited
Marketing authorisation number
Carprogesic Tablets 20 mg Vm 02000/4248.
Carprogesic Tablets 50 mg Vm 02000/4249.
| 
